CIA SANEAMENTO BASICO DE-ADR
SBSNYSETrading Snapshot
- Day Range
- $5.11 – $5.24
- 52-Week Range
- $4.43 – $7.16
- Volume
- $7.20B
- Avg Volume
- $5.27B
- Shares Outstanding
- 3.42B
- Next Earnings
- Dec 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $37.34B
- Last Q Revenue
- $10.44B
- P/E Ratio
- 2.3
- P/S Ratio
- 2.3x
- EPS (TTM)
- $11.74
- Dividend Yield
- 2.58%
- Dilution (1yr)
- +0.1%
Why Investors Own SBS
- ✓High-growth profile — revenue up +27.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CIA SANEAMENTO BASICO DE-ADR
SBS
StockOtter · stockotter.spaceAbout CIA SANEAMENTO BASICO DE-ADR
SABESP, or Companhia de Saneamento Básico do Estado de São Paulo, is a key utility provider specializing in water and sewage services for residential, commercial, industrial, and governmental clients. Its offerings are comprehensive, spanning water supply, sanitary sewage systems, urban rainwater management and drainage, municipal cleaning, and solid waste management. The company's operations also encompass planning, system operation, maintenance, and the commercialization of energy. As of December 31, 2021, SABESP delivered water services to approximately 27.8 million people through 9.8 million connections and provided sewage services to about 24.6 million individuals via 8.4 million connections. Its expansive infrastructure included 88,904 kilometers of water pipes and transmission lines, alongside 61,122 kilometers of sewer lines. Furthermore, through special purpose companies, SABESP extends its water and/or sewage provisions to four additional municipalities. The company was established in 1954 and is headquartered in São Paulo, Brazil.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
YSS Investors Have Opportunity to Lead York Space Systems, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against York Space Systems, Inc. (“York” o
HONA Investors Have Opportunity to Lead Honeywell Aerospace Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Honeywell Aerospace Inc. (“Honeywel
INV Investors Have Opportunity to Lead Innventure, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Innventure, Inc. (“Innventure” or “
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution, targeting an NDA fili
AVEX Investors Have Opportunity to Lead AEVEX Corp. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AEVEX Corp. (“Aevex” or “the Compa
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. (“Aard